The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype

Maximilian Linxweiler1, Fengshen Kuo2, Nora Katabi3

  • 1Human Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Abstract

Insights

Salivary gland carcinomas (SGCs) show distinct immune microenvironments and neoantigen landscapes. Understanding these differences, particularly in salivary duct carcinomas versus adenoid cystic carcinomas, is key for developing effective immunotherapies.

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Salivary gland carcinomas (SGCs) are rare, aggressive cancers with poor outcomes due to recurrence, metastasis, and limited therapies.
  • Current immune checkpoint blockade efficacy is low, necessitating deeper understanding of SGCs' molecular and immunological features.

Purpose of the Study:

  • To characterize the immune microenvironment and neoantigen landscape in SGCs.
  • To identify potential immunologic vulnerabilities for precision immunotherapy.

Main Methods:

  • RNA sequencing (RNA-seq) of 76 SGC tumors (ACC, MECA, SDC) and exome sequencing in 37 cases.
  • Analysis of transcriptomic profiles, immune cell infiltration, T-cell activation/dysfunction, somatic mutations, and neoantigens.

Main Results:

  • Salivary duct carcinomas (SDCs) showed high immune infiltration, T-cell dysfunction, and high mutational load.
  • Adenoid cystic carcinomas (ACCs) displayed immune exclusion, M2 macrophages, myeloid-derived suppressor cells, and low mutational load.
  • Myoepithelial carcinomas (MECs) were heterogeneous; immune infiltration correlated with neoantigens and aggressive behavior across all SGCs.

Conclusions:

  • SGC immune escape mechanisms vary by histology, offering distinct therapeutic targets.
  • These findings provide crucial insights for guiding precision immunotherapy strategies in SGCs.